Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Erica Mayer

Dana-Farber Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (11)

Joohyuk Sohn

Yonsei University College of Medicine

SOUTH KOREA

View details

Adam Brufsky

University of Pittsburgh Medical Center

UNITED STATES

View details

Michail Ignatiadis

Leader Investigator Initiated Trials

Institut Jules Bordet

BELGIUM

View details

Angela DeMichele

University of Pennsylvania

UNITED STATES

View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES

View details

Antonio Giordano

Dana-Farber Cancer Institute

UNITED STATES

View details

seamus o'reilly

Clinical Lead

Cork University Hospital

IRELAND

View details

Kathy Miller

Indiana University Bloomington

UNITED STATES

View details

Claudine Isaacs

Professor of Medicine

Georgetown University

UNITED STATES

View details

Alexandra Thomas

Associate Director for Translational Science

Duke University

UNITED STATES

View details

Yue Zheng

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Erica Mayer

Research Interests

Explore related searches

Articles (20)

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer

Giredestrant plus Everolimus in Advanced Breast Cancer

Cardiovascular Toxicity of CDK4/6 Inhibitors in Breast Cancer

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy

Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer

Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer

Oncology’s ongoing struggle with evaluating quality of life limiting, treatment-related toxicity

Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer

Inavolisib-Based Triplet Therapy for PIK3CA -Mutated Hormone Receptor+/HER2- Breast Cancer: Clinical Implications and Practical Considerations

Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2− early breast cancer: a discrete choice survey study

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?

Is Preventative Oophorectomy Safe?

Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer

Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care

Collaborators (11)

Joohyuk Sohn

Adam Brufsky

Michail Ignatiadis

Angela DeMichele

Yara G Abdou

Antonio Giordano

seamus o'reilly

Kathy Miller

Claudine Isaacs

Alexandra Thomas

Yue Zheng

Make your next move.